Welcome to our dedicated page for Ensysce Biosciences news (Ticker: enscw), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences Inc. (ENSCW) is a clinical-stage biopharmaceutical innovator developing abuse-deterrent opioid therapies using its proprietary TAAP and MPAR platforms. This page provides timely updates on the company’s advancements in pain management and opioid use disorder treatment.
Investors and stakeholders will find verified news on clinical trial milestones, regulatory developments, and strategic collaborations. Key updates include progress on PF614 (TAAP-activated pain therapy), PF614-MPAR (overdose-resistant candidate), and FDA-designated programs.
This resource consolidates press releases covering financial results, intellectual property expansions, and manufacturing partnerships. Bookmark this page to track Ensysce’s progress in addressing critical public health challenges through safer prescription drug technologies.
Ensysce Biosciences announced that its Chief Commercial Officer, Geoff Birkett, will participate in the EPHMRA 2024 Annual Conference in London from June 24-27, 2024. Birkett will be part of the opening panel discussion on June 25, titled 'The Future of Healthcare Market Research,' and will lead a presentation on June 26 about customer engagement strategy development. Birkett, known for his expertise in market research and commercialization, is pivotal in preparing for the launch of Ensysce's lead product, PF614, and the innovative follow-on drug, PF614-MPAR, an opioid with oral overdose protection. His insights have been essential in advancing Ensysce's portfolio aimed at severe pain relief while mitigating opioid misuse and overdose.
Ensysce Biosciences has renewed its collaboration with Quotient Sciences to advance the clinical development of its overdose protection platform, PF614-MPAR. This innovative opioid product, designed to prevent overdose by shutting off opioid release when too many pills are ingested, is undergoing a Phase 1b study to evaluate its efficacy and safety across different doses. The study, PF614-MPAR-102, will assess doses of 25 mg, 50 mg, and 100 mg administered twice daily for five days. PF614-MPAR, which has received Breakthrough Therapy designation from the FDA, aims to provide a safer solution for severe pain management and address the ongoing opioid overdose crisis in the U.S.
Ensysce Biosciences reported their first quarter 2024 financial results, highlighting progress in their clinical programs with FDA breakthrough therapy designations for their lead opioid products, PF614 and PF614-MPAR. The company received positive feedback and guidance from the FDA, affirming their path to regulatory approval and commercialization. Ensysce is set to begin Phase 3 clinical trials in the second half of 2024, showcasing their innovative TAAP and MPAR opioids for severe pain relief with reduced abuse potential.
FAQ
What is the current stock price of Ensysce Biosciences (enscw)?
